{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T11:41:20Z","timestamp":1789472480938,"version":"build-2803163510"},"reference-count":27,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Ophthalmol"],"published-print":{"date-parts":[[2019,8,1]]},"DOI":"10.1001\/jamaophthalmol.2019.1947","type":"journal-article","created":{"date-parts":[[2019,7,11]],"date-time":"2019-07-11T15:00:48Z","timestamp":1562857248000},"page":"914","source":"Crossref","is-referenced-by-count":36,"title":["Incidence of New Choroidal Neovascularization in Fellow Eyes of Patients With Age-Related Macular Degeneration Treated With Intravitreal Aflibercept or Ranibizumab"],"prefix":"10.1001","volume":"137","author":[{"given":"Ravi","family":"Parikh","sequence":"first","affiliation":[{"name":"Vitreous Retina Macula Consultants of New York, New York"},{"name":"Department of Ophthalmology, New York University School of Medicine, New York"},{"name":"Retina Service, Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Avery","sequence":"additional","affiliation":[{"name":"California Retina Consultants, Santa Barbara"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namrata","family":"Saroj","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals Inc, Tarrytown, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desmond","family":"Thompson","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals Inc, Tarrytown, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. Bailey","family":"Freund","sequence":"additional","affiliation":[{"name":"Vitreous Retina Macula Consultants of New York, New York"},{"name":"Department of Ophthalmology, New York University School of Medicine, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"6","key":"eoi190037r1","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.ajo.2010.01.007","article-title":"Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials.","volume":"149","author":"Barbazetto","year":"2010","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"eoi190037r2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/S0161-6420(97)30368-6","article-title":"The five-year incidence and progression of age-related maculopathy: the Beaver Dam Eye Study.","volume":"104","author":"Klein","year":"1997","journal-title":"Ophthalmology"},{"issue":"2","key":"eoi190037r3","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.ophtha.2006.10.040","article-title":"Fifteen-year cumulative incidence of age-related macular degeneration: the Beaver Dam Eye Study.","volume":"114","author":"Klein","year":"2007","journal-title":"Ophthalmology"},{"issue":"6","key":"eoi190037r4","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1016\/j.ophtha.2003.08.042","article-title":"Five-year incidence of age-related maculopathy: the Visual Impairment Project.","volume":"111","author":"Mukesh","year":"2004","journal-title":"Ophthalmology"},{"issue":"4","key":"eoi190037r5","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1001\/archopht.121.4.519","article-title":"The risk and natural course of age-related maculopathy: follow-up at 6 1\/2 years in the Rotterdam study.","volume":"121","author":"van Leeuwen","year":"2003","journal-title":"Arch Ophthalmol"},{"issue":"4","key":"eoi190037r6","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.ophtha.2004.10.047","article-title":"Risk factors for the incidence of advanced age-related macular degeneration in the Age-Related Eye Disease Study (AREDS) AREDS report no. 19.","volume":"112","author":"Clemons","year":"2005","journal-title":"Ophthalmology"},{"issue":"10","key":"eoi190037r7","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1016\/j.ophtha.2013.03.017","article-title":"Incidence of choroidal neovascularization in the fellow eye in the comparison of age-related macular degeneration treatments trials.","volume":"120","author":"Maguire","year":"2013","journal-title":"Ophthalmology"},{"issue":"10","key":"eoi190037r8","doi-asserted-by":"publisher","first-page":"1695.e1","DOI":"10.1016\/j.ophtha.2006.05.064","article-title":"Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy.","volume":"113","author":"Avery","year":"2006","journal-title":"Ophthalmology"},{"issue":"12","key":"eoi190037r9","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1016\/j.ophtha.2007.09.012","article-title":"Pharmacokinetics of intravitreal ranibizumab (Lucentis).","volume":"114","author":"Bakri","year":"2007","journal-title":"Ophthalmology"},{"issue":"5","key":"eoi190037r10","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.ophtha.2007.01.017","article-title":"Pharmacokinetics of intravitreal bevacizumab (Avastin).","volume":"114","author":"Bakri","year":"2007","journal-title":"Ophthalmology"},{"issue":"6","key":"eoi190037r11","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1007\/s10792-014-9921-0","article-title":"Significant reduction of diabetic macular edema following intravitreal ranibizumab injection in the fellow eye.","volume":"34","author":"Rotsos","year":"2014","journal-title":"Int Ophthalmol"},{"issue":"9","key":"eoi190037r12","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1097\/IAE.0b013e318213da43","article-title":"Bilateral effect of unilateral ranibizumab in patients with uveitis-related macular edema.","volume":"31","author":"Acharya","year":"2011","journal-title":"Retina"},{"issue":"8","key":"eoi190037r13","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1089\/jop.2013.0049","article-title":"Comparison of the effect of unilateral intravitreal bevacizumab and ranibizumab injection on diabetic macular edema of the fellow eye.","volume":"29","author":"Bakbak","year":"2013","journal-title":"J Ocul Pharmacol Ther"},{"issue":"6","key":"eoi190037r14","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1038\/eye.2014.94","article-title":"Fellow eye effect of unilateral intravitreal bevacizumab injection in eyes with diabetic macular edema.","volume":"28","author":"Hanhart","year":"2014","journal-title":"Eye (Lond)"},{"issue":"7","key":"eoi190037r15","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/j.ophtha.2012.04.015","article-title":"Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial.","volume":"119","author":"Chakravarthy","year":"2012","journal-title":"Ophthalmology"},{"issue":"12","key":"eoi190037r16","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1136\/bjophthalmol-2014-305252","article-title":"Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD.","volume":"98","author":"Avery","year":"2014","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"eoi190037r17","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ophtha.2013.08.011","article-title":"Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies.","volume":"121","author":"Schmidt-Erfurth","year":"2014","journal-title":"Ophthalmology"},{"issue":"14","key":"eoi190037r18","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration.","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N Engl J Med"},{"issue":"3","key":"eoi190037r19","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1001\/jamaophthalmol.2013.6636","article-title":"Ten-year follow-up of age-related macular degeneration in the Age-Related Eye Disease Study: AREDS report No. 36.","volume":"132","author":"Chew","year":"2014","journal-title":"JAMA Ophthalmol"},{"issue":"9","key":"eoi190037r20","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1016\/j.ophtha.2008.03.008","article-title":"Risk factors for choroidal neovascularization and geographic atrophy in the complications of age-related macular degeneration prevention trial.","volume":"115","author":"Complications of Age-related Macular Degeneration Prevention Trial (CAPT) Research Group","year":"2008","journal-title":"Ophthalmology"},{"issue":"2","key":"eoi190037r21","doi-asserted-by":"publisher","first-page":"e154","DOI":"10.1111\/aos.2015.93.issue-2","article-title":"Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: a randomised, prospective trial.","volume":"93","author":"Zehetner","year":"2015","journal-title":"Acta Ophthalmol"},{"key":"eoi190037r22","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.ajo.2016.06.042","article-title":"Optical coherence tomography angiography: a useful tool for diagnosis of treatment-na\u00efve quiescent choroidal neovascularization.","volume":"169","author":"Carnevali","year":"2016","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"eoi190037r23","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.ophtha.2017.08.030","article-title":"Natural history of subclinical neovascularization in nonexudative age-related macular degeneration using swept-source OCT angiography.","volume":"125","author":"de Oliveira Dias","year":"2018","journal-title":"Ophthalmology"},{"issue":"6","key":"eoi190037r24","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/j.ophtha.2016.01.044","article-title":"Optical coherence tomography angiography of asymptomatic neovascularization in intermediate age-related macular degeneration.","volume":"123","author":"Roisman","year":"2016","journal-title":"Ophthalmology"},{"issue":"2","key":"eoi190037r25","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1023\/A:1005848806641","article-title":"Indocyanine green angiographic findings in fellow eyes of patients with unilateral occult neovascular age-related macular degeneration.","volume":"21","author":"Schneider","year":"1997","journal-title":"Int Ophthalmol"},{"issue":"9","key":"eoi190037r26","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1016\/S0161-6420(98)99030-3","article-title":"Indocyanine-green videoangiography of drusen as a possible predictive indicator of exudative maculopathy.","volume":"105","author":"Hanutsaha","year":"1998","journal-title":"Ophthalmology"},{"key":"eoi190037r27","unstructured":"US National Library of Medicine; ClinicalTrials.gov. Intravitreal aflibercept injection versus sham as prophylaxis against conversion to neovascular AMD (PRO-CON). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02462889. Accessed September 18, 2017."}],"container-title":["JAMA Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/article-pdf\/137\/8\/914\/17773802\/jamaophthalmology_parikh_2019_oi_190037.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T15:01:21Z","timestamp":1565276481000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/fullarticle\/2737865"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,1]]},"references-count":27,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaophthalmol.2019.1947","relation":{},"ISSN":["2168-6165"],"issn-type":[{"value":"2168-6165","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8,1]]}}}